About Journal of Immune Based Therapies and Vaccines

What is Journal of Immune Based Therapies and Vaccines?

Journal of Immune Based Therapies and Vaccines is an Open Access, peer-reviewed, online journal dedicated to all aspects of therapeutic applications of immunology.

Journal of Immune Based Therapies and Vaccines aims to advance the understanding of specific immunological mechanisms involved in protection for efficacious vaccines and the immune correlates of the therapeutic action of Immune Based Therapies (IBTs). The areas of vaccines and IBTs encompass many different disciplines as immune based therapies and vaccines are now being developed for infectious diseases, transplantation, cancer, allergic diseases, and autoimmune diseases.

Due to rapid developments, there is a need for a journal that is focused solely on immune based therapies and vaccines. The goal of this journal is to provide an objective peer review process conducted by those knowledgeable in the field. The clear advantage of this journal is the rapid dissemination of high-quality, Open Access scientific work, which should provoke additional scientific hypothesis, thereby advancing the field.

Content overview

Journal of Immune Based Therapies and Vaccines considers the following types of articles:

• Original research - reports of data from original research related to IBTs and vaccines or related to immune pathogenesis of diseases targeted by IBTs and vaccines
• Reviews - summaries of recent insights in specific research areas within the scope of Journal of Immune Based Therapies and Vaccines. They can be submitted either upon specific invitation or editorial acceptance of an author's proposal. To submit a proposal, authors should send a tentative title and abstract to the Editorial Office and justify their expertise in the target area, and also both the scientific relevance and the lack of recent reviews on the topic.

Peer review policies

Manuscripts submitted to Journal of Immune Based Therapies and Vaccines will be reviewed by experts in the field. If deemed acceptable for publication, articles may require minimal or substantial modification. Authors are requested to respond to each reviewer comment. Ultimately, the Editor-in-Chief or editorial board members make the decision to accept or reject. Following acceptance all efforts are made to publish the article as quickly as possible.

Edited by Ronald B Moss, Journal of Immune Based Therapies and Vaccines is supported by an international Editorial Board.

Publishing in Journal of Immune Based Therapies and Vaccines

All articles will be listed in PubMed immediately upon acceptance (after peer review), and will be covered by PubMed Central, CAS and Embase.

Articles in Journal of Immune Based Therapies and Vaccines should be cited in the same way as articles in a traditional journal. However, because articles in this journal are not printed, they do not have page numbers. Instead, they have a unique article number.

The following citation:

J Immune Based Ther Vaccines 2004, 2:1

refers to article 1 from volume 2 of the journal.

As an online journal, Journal of Immune Based Therapies and Vaccines does not have issue numbers. Each volume corresponds to a calendar year.

To keep up to date with the latest articles from Journal of Immune Based Therapies and Vaccines, why not register to receive alerts? Registration also enables you to customise your subject areas of interest, store your searches, and submit your manuscripts.

Submission of manuscripts

Manuscripts should be submitted electronically to Journal of Immune Based Therapies and Vaccines using the online submission system. Full details of how to submit a manuscript are given in the instructions for authors.

General journal policies

Journal of Immune Based Therapies and Vaccines is published  by BioMed Central, an independent publisher committed to ensuring peer-reviewed biomedical research is Open Access. That means it is freely and universally accessible online, it is archived in at least one internationally recognised free access repository, and its authors retain copyright, allowing anyone to reproduce or disseminate articles, according to the BioMed Central copyright and licence agreement. Journal of Immune Based Therapies and Vaccines however, has taken this further by making all its content Open Access.

Journal of Immune Based Therapies and Vaccines's articles are archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also in repositories at the University of Potsdam in Germany, at INIST in France and in e-Depot, the National Library of the Netherlands' digital archive of all electronic publications. The journal is also participating in the British Library's e-journals pilot project, and plans to deposit copies of all articles with the British Library.

BioMed Central is working closely with the Thomson Reuters (ISI) to ensure that citation analysis of articles published in Journal of Immune Based Therapies and Vaccines will be available.

Journal of Immune Based Therapies and Vaccines is able to deliver summaries of frequently updated content via Really Simple Syndication (RSS) feeds. These are accessible via the orange "XML" button at the top of the list of recent articles or the list of most accessed articles. For more information about RSS feeds see our publisher's website.

For further information about general policies please see the instructions for authors.